Fifth Third Bancorp boosted its stake in Chemed Co. (NYSE:CHE – Get Rating) by 37.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,876 shares of the company’s stock after acquiring an additional 1,052 shares during the quarter. Fifth Third Bancorp’s holdings in Chemed were worth $1,978,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. North Point Portfolio Managers Corp OH raised its position in shares of Chemed by 0.6% in the 4th quarter. North Point Portfolio Managers Corp OH now owns 20,949 shares of the company’s stock valued at $10,693,000 after purchasing an additional 132 shares in the last quarter. Pallas Capital Advisors LLC raised its position in shares of Chemed by 2.3% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,673 shares of the company’s stock valued at $1,829,000 after acquiring an additional 81 shares in the last quarter. Xponance Inc. raised its position in shares of Chemed by 8.9% during the 4th quarter. Xponance Inc. now owns 2,482 shares of the company’s stock valued at $1,267,000 after acquiring an additional 202 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Chemed by 61.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,839 shares of the company’s stock valued at $939,000 after acquiring an additional 703 shares in the last quarter. Finally, Veriti Management LLC acquired a new stake in shares of Chemed during the 4th quarter valued at approximately $231,000. Hedge funds and other institutional investors own 91.12% of the company’s stock.
Insiders Place Their Bets
In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $507.32, for a total value of $1,014,640.00. Following the completion of the transaction, the chief executive officer now owns 121,613 shares of the company’s stock, valued at $61,696,707.16. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Kevin J. Mcnamara sold 3,000 shares of the stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $526.27, for a total value of $1,578,810.00. Following the completion of the transaction, the chief executive officer now owns 118,613 shares of the company’s stock, valued at $62,422,463.51. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, March 9th. The stock was sold at an average price of $507.32, for a total value of $1,014,640.00. Following the completion of the transaction, the chief executive officer now directly owns 121,613 shares of the company’s stock, valued at approximately $61,696,707.16. The disclosure for this sale can be found here. Insiders have sold 9,000 shares of company stock valued at $4,686,450 over the last three months. Company insiders own 4.03% of the company’s stock.
Wall Street Analysts Forecast Growth
Chemed Price Performance
Shares of NYSE CHE opened at $548.81 on Friday. Chemed Co. has a 1-year low of $430.16 and a 1-year high of $553.41. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.92 and a quick ratio of 0.88. The business’s fifty day moving average price is $517.87 and its two-hundred day moving average price is $497.43. The firm has a market capitalization of $8.20 billion, a PE ratio of 33.20, a P/E/G ratio of 2.97 and a beta of 0.53.
Chemed (NYSE:CHE – Get Rating) last issued its earnings results on Friday, February 24th. The company reported $5.39 earnings per share for the quarter, topping the consensus estimate of $5.30 by $0.09. Chemed had a return on equity of 41.54% and a net margin of 11.69%. The firm had revenue of $546.65 million for the quarter, compared to analyst estimates of $546.60 million. During the same period last year, the company earned $5.25 earnings per share. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, research analysts expect that Chemed Co. will post 20.85 EPS for the current year.
Chemed Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, March 17th. Shareholders of record on Monday, February 27th were given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Friday, February 24th. Chemed’s dividend payout ratio is presently 9.20%.
Chemed Profile
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Articles
- Get a free copy of the StockNews.com research report on Chemed (CHE)
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
- FedEx Takes Flight; Analysts See More Gains Ahead
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Get Rating).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
